Overview

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

Status:
COMPLETED
Trial end date:
2023-08-24
Target enrollment:
Participant gender:
Summary
This study comprised of 2 parts, Part A and Part B. Part B will only be conducted if the relative bioavailability of the tablet formulation was at least 70% of the capsule formulation.
Phase:
PHASE1
Details
Lead Sponsor:
Sumitomo Pharma America, Inc.
Treatments:
TP 3654